|
KMID : 1039120190080010054
|
|
Clinical and Experimental Vaccine Research
2019 Volume.8 No. 1 p.54 ~ p.63
|
|
|
Nucleoprotein vaccine induces cross-protective cytotoxic T lymphocytes against both lineages of influenza B virus
|
|
Lee So-Young
Kang Jung-Ok
Chang Jun
|
|
|
Abstract
|
|
|
Purpose: The influenza B virus diverges into two antigenically distinct lineages: B/Yamagata and B/Victoria. Influenza B is the dominant circulating virus during some influenza seasons, and recent data demonstrated that influenza A and B infection similarly cause severe clinical symptoms in hospitalized patients. Nucleoprotein (NP) is a good target for a universal influenza vaccine. This study investigated whether NP epitope variation within two lineages affects the dominant cytotoxic T lymphocyte (CTL) responses induced by vaccination and the resultant protective immunity.
Materials and Methods: The NP of B/Yamagata/16/1988, the representative strain of the Yamagata lineage, includes a dominant CTL epitope, FSPIRITFL, while B/Shangdong/7/1997 from the Victoria lineage has one amino acid difference in this sequence, FSPIRVTFL. Two recombinant replication-deficient adenovirus (rAd)-vectored vaccines expressing either NP were prepared (rAd/B-NP(I) and rAd/B-NP(V), respectively) and administered to BALB/c mice intranasally. To examine the efficacy of vaccination, antibody responses, CTL responses, and morbidity/mortality after challenge were measured.
Results: Both vaccines induce similar antibody and CD8 T-cell responses cross-reacting to both epitopes, and also confer cross-protection against both lineages regardless of amino acid difference.
Conclusion: The rAd-vectored vaccine expressing the NP could be developed as universal influenza B vaccine which provides broader protection.
|
|
|
KEYWORD
|
|
|
Influenza B virus, Cross protective immunity, Nucleoproteins, Cytotoxic T lymphocytes, Recombinant adenovirus, Epitope
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|